ERBB2 and thyroid gland carcinoma: Researchers are now investigating combinations of targeted inhibitors, including dabrafenib (BRAFV600E inhibitor) and lapatinib (HER2/neu and EGFR inhibitor) in refractory and inoperable BRAFV600E-positive thyroid cancer.